All News
Prednisone remains both lifeline and liability.
New PRED-SAFE SDM tool helps patients and clinicians navigate that tension—visualizing benefits and harms to guide tapering. In pilot testing, 93% had no residual decisional conflict.
@RheumNow #ACR25 Abstract#1052 #ACRbest https://t.co/CgQ75N7A1p
Jiha Lee JihaRheum ( View Tweet)
@RheumNow on virtual learning:
It’s integrated in clinical care, research and #MedEd
How to manage info overload?
- schedule, make use of tools
- use AI to curate, analyze & focus
#ACR25 @rheumarhyme https://t.co/ogCezlnxUP
Links:
sheila RHEUMarampa ( View Tweet)
#1263 More from our health literacy work!
@KingsCollegeNHS, 11 distinct health literacy profiles were identified from 263 rheum patients. Lower literacy linked to unemployment & non-White ethnicity, highlighting equity gaps in care & need for improved resources
@RheumNow #ACR25 https://t.co/QxzMFLykyE
Mrinalini Dey DrMiniDey ( View Tweet)
RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
@RheumNow on Social Media:
✧ virtual learning is the future of medicine
✧use digital strategies to filter good data online- AI can help focus interests & stay up to date - ex. Consensus or Feedly!
✧ peer to peer learning through social media enhances learning
#ACR25 https://t.co/n6MzhYoz0n
Kailey Singh doctorkails ( View Tweet)
Eat #fibre helps #rheumatoid #arthritis!
#RCT #RA w #MTX
Adding #super fibre
Mean #DAS28 3.8
7TJC, SJC2
Small N +RCT
Super fibre group
⬆️ #EULAR response
✅ improve #TH17 &TREG response
🤷♀️ tolerability and ease to use dietary super fibre
#ACR25 @RheumNow @ACRheum abst#LB15 https://t.co/ME6bsj4Ec7
Links:
Janet Pope Janetbirdope ( View Tweet)
Is MTX worth anything in GCA?
METOGiA: MTX 52w vs TCZ 52w for GCA
MTX didn’t achieve non-inferiority to TCZ, but:
- clearly it does something
- continue both >1y: after MTX/TCZ therapy ended, they ended up with same relapse-free survival, cumulative GC
#ACR25 ABST0891 @RheumNow https://t.co/WvvkHKIXuQ
Links:
David Liew drdavidliew ( View Tweet)
List of GLP1 agonists approved currently..would they have effects in #OA
Session title is should we gave them to everyone?
#ACR25 @RheumNow https://t.co/dXwB6Jkg8C
Bella Mehta bella_mehta ( View Tweet)
Open label noninferiority RCT "METOGiA" in GCA
TCZ improved relapse free survival (83% vs 67% MTX) & pred free remission (81% vs 61% MTX) wk 52. Ignore the weird primary endpt at week 78
Everyone also got pred; are we sure MTX works at all?
@RheumNow #ACR25 #ACRBest Abstr#0891 https://t.co/i48JBnawB7
Links:
Mike Putman EBRheum ( View Tweet)
#1077 More health literacy work from our group!
995 people with inflammatory arthritis: lower health literacy linked to higher absenteeism & presenteeism
Those with highest HLQ scores were mostly retired with better engagement in care
@RheumNow #ACR25
Come check out our poster! https://t.co/CaqzkjMWYB
Mrinalini Dey DrMiniDey ( View Tweet)
#ACR25 Abstr#1526 Finally it’s here! Consensus-based guidance on GC #steroid tapering in patients with #SLE. Included considerations before tapering, tapering schedules and monitoring during tapering. Looking forward to the uptake and hearing patients’ views @RheumNow #ACRBest https://t.co/FFl2TFhtTa
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
In the #ACR25 Great AI debate, @RADoctor shows automated ultrasound scanning - one legitimately promising application ready very soon.
I’ve written about this work (ARTHUR/DIANA) for @RheumNow last year - check it out:
https://t.co/Zq4ywEjspi https://t.co/3RYCVunE3a
Links:
David Liew drdavidliew ( View Tweet)
@JYazdanyMD in the #ACR25 Great AI Debate details out three key risks of AI in rheumatology:
- bias at scale
- erosion of skills
- data regulatory issues
(for what it’s worth, amongst all the potential upside, I think it’s very real. It’s up to us to make it better)
@RheumNow https://t.co/FyNes40Z7q
David Liew drdavidliew ( View Tweet)
Summary take home points by Dr Highland
1. PAH and PH-ILD are associated with high mortality in patients with SARDs
2. Multimodal and early screening is recommended
3. “It takes a village” work with Pulm and Cardiology colleagues
@RheumNow #ACR2025 https://t.co/Xa7TecMOIe
Gabriela Martinez Zayas, MD MartinezZayasMd ( View Tweet)
In the #ACR25 Great AI Debate, @RADoctor and @JYazdanyMD prepared independently, but in consecutive moments agree (in a very illustrative way):
guardrails - they need to happen
@RheumNow https://t.co/ccLLC3adxG
Links:
David Liew drdavidliew ( View Tweet)
#1627 SLR informing the 2025 @eular_org recommendations for PMR & LVV 🔍
141 studies (30 RCTs) reviewed: new & further evidence for IL-6, JAK & B-cell-targeted therapies. Data will underpin updated management guidance. @RheumNow #ACR25
Mrinalini Dey DrMiniDey ( View Tweet)
#0854 @Official_ASAS & @SPARTAN_Updates revised #axSpA criteria meet targets: Sn 79.5% / Sp 90.4%.
Imaging is central (SIJ MRI + structural lesions) with focused clinical items: HLA-B27, IBP, uveitis, IBD, heel enthesitis, psoriasis, ↑CRP
@RheumNow #ACR25 https://t.co/i2d12y9HcD
Mrinalini Dey DrMiniDey ( View Tweet)
Summary of (some) drugs in the pipeline for management of PAH. Slide credits: Dr Benjamin Freed @RheumNow #ACR2025 https://t.co/qazQNk4ovR
Gabriela Martinez Zayas, MD MartinezZayasMd ( View Tweet)
#1614 Another SLR informing the 2025 EULAR recommendations for PMR & LVV 🧭
Fast-track clinics cut blindness & diagnostic delays; multimodal imaging pathways outperform biopsy alone. Key data shaping future referral & diagnosis guidance. @RheumNow #ACR25
Mrinalini Dey DrMiniDey ( View Tweet)
#ACR25 Abstr#1525 Find me at poster hall. Super-responders exist with rituximab, not just confined to CAR-T! Our cohort study = 23/114 (20%) had resp duration >3-yrs; 15/23 were IS-Free. Poor prognostics (Non-White, APS) & shorter #SLE duration predicted super-tesponse @RheumNow https://t.co/nJQFmiIj2n
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
